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Abstract—Evidence from cohort studies and a randomized clinical trial indicates that annual vaccination against seasonal
influenza prevents cardiovascular morbidity and all-cause mortality in patients with cardiovascular conditions. The American
Heart Association and American College of Cardiology recommend influenza immunization with inactivated vaccine
(administered intramuscularly) as part of comprehensive secondary prevention in persons with coronary and other
atherosclerotic vascular disease (Class I, Level B). Immunization with live, attenuated vaccine (administered intranasally) is
contraindicated for persons with cardiovascular conditions. It is important to note that influenza vaccination coverage levels
overall and in this population remain well below national goals and are marked by disparities across different age and ethnic
groups. One of the barriers to vaccination for patients with cardiovascular disease is that cardiology practices frequently do
not stock and administer influenza vaccine. Healthcare providers who treat individuals with cardiovascular disease can help
improve influenza vaccination coverage rates by providing and strongly recommending vaccination to their patients before
and throughout the influenza season. (J Am Coll Cardiol 2006;48:1498–1502)
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Influenza is estimated to cause36 000 deaths and 225 000excess hospitalizations in the United States every year.
Children and adults with chronic conditions, including car-
diovascular disease (CVD) and diabetes, are particularly
vulnerable to complications of influenza infection (1–3).
Immunization against seasonal influenza has a critical but
perhaps underappreciated role in the prevention of morbidity
and mortality in patients with CVD. Recognizing the impor-
tance of vaccination, the American Heart Association (AHA)
and American College of Cardiology (ACC) recommend
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influenza vaccination as part of comprehensive secondary pre-
vention in children and adults with coronary and other athero-
sclerotic vascular disease (4). Influenza vaccination is now
recommended with the same enthusiasm as control of choles-
terol, blood pressure, and other modifiable risk factors. Never-
theless, influenza vaccination coverage levels among persons
with CVD (34% nationally in 2005) remain well below national
goal s and are marked by disparities across age categories and
ethnic groups.
The challenge to the profession is to translate the recom-
mendation for influenza vaccination into action. This trans-
lation is challenging to the cardiovascular community be-
cause immunization falls out of what is commonly perceived
as the realm of typical cardiology practice. Currently, about
one half of cardiology practices nationwide do not stock
influenza vaccine (5). A recent study indicated that the most
effective ways to increase influenza vaccination coverage
among persons with CVD are to make influenza vaccine
available at all cardiology practices and to have physicians
strongly recommend the vaccine to their patients (6).
This Science Advisory summarizes information for cardio-
vascular care providers on influenza and vaccination against
influenza. It focuses on the increased risk and complications
of influenza for persons with CVD, the effectiveness of
infl uenza vaccine for secondary prevention of cardiovascular
events, and opportunities for healthcare providers to improve
rates of vaccination against influenza among persons with
cardiovascular conditions. The purpose of this advisory is to
equip practitioners with the information they need to adopt
these recommendations into practice and ensure that cardio-
vascular patients have routine, annual influenza vaccination.
Influenza Illness and Influenza Vaccine
Two types of influenza viruses, influenza A and B, cause
epidemic human disease in a seasonal pattern (7). Influenza A
viruses are further classified into subtypes based on 2 surface
antigens (hemagglutinin and neuraminidase), and influenza A
and   B viruses are both further separated into groups (identi-
fied geographically) on the basis of other antigenic charac-
teri stics (2). Immunity to surface antigens protects individuals
agai nst infection and, should they be infected, against severe
disease (8), but antibodies against one influenza virus type or
subtype confer little or no immunity against other types and
subtypes. Frequent antigenic changes (“antigenic drift”) gen-
erate new influenza virus variants that cause seasonal epi-
demics. Pandemic influenza may occur when antigenic shifts
are more pronounced than usual (2).
Vaccination is the primary mode of prophylaxis against
influenza. The US Advisory Committee on Immunization
Practices (ACIP) of the Centers for Disease Control and
Prevention recommends annual influenza vaccination for all
persons50 years of age, for children 6 months to 59 months
of age, for women who will be pregnant during influenza
season, and for adults and children with chronic conditions,
including CVD and diabetes (2). These groups are also
prioritized during influenza seasons when supplies of influ-
enza vaccine are expected to be lower than the demand.
Although antiviral medications may be used for short-term
prophylaxis of high-risk persons with known exposure to a
case of influenza, as well as for treatment of influenza cases,
these medications are not recommended as a general preven-
tive strategy at the population level (2).
Two forms of the vaccine exist: one inactivated (administered
intramuscularly) and the other in a live, attenuated form (admin-
istered intranasally). Each year, influenza vaccine is reformu-
lated to include 3 antigens that are representative of viruses that
are expected to circulate during the forthcoming influenza
season. In inactivated vaccines, only subvirion and purified
surface antigens are used, which makes the vaccines noninfec-
tious. It is important to note that individuals with CVD should
not receive the live, attenuated influenza vaccine because it can
cause influenza illness in this high-risk population (2).
The optimal time for influenza vaccination is usually
September through November for high-risk persons, includ-
ing persons with CVD. This timing maximizes the benefit of
vaccination before the typical onset of influenza activity in
the United States. However, as long as vaccine is available,
influenza vaccination should continue into January or later
because influenza activity most commonly peaks in January,
February, or March in the United States (2). Vaccination
efforts late in the season are especially important when
vaccine supply is delayed in the fall.
Persons with known anaphylactic hypersensitivity to eggs
or a history of Guillain-Barre syndrome should not receive
the inactivated influenza vaccine without first consulting a
physician. If a person eligible for vaccination has moderate-
to-severe acute febrile illness, vaccination should be delayed
until symptoms have resolved (2).
Influenza Among Patients With CVD
Influenza-related death is more common among individuals
with CVD than among patients with any other chronic
condition (9). Influenza can exacerbate underlying medical
conditions, including CVD and diabetes, and can also lead to
viral pneumonia, secondary bacterial pneumonia, or a coin-
fection with other viruses or bacteria (10). Epidemiological
data indicate that risks for complications, hospitalizations,
and death from influenza are higher for individuals at the
extremes of age (5 years old, 65 years old) and for
persons with chronic medical conditions than for healthy
older children and younger adults (1,11–16).
The mechanism through which influenza may cause cardio-
vascular events is not well understood. One current hypothesis is
that the inflammatory response of the body to viral infection
leads to production of autoantibodies to modified low-density
lipoprotein, which causes the development and progression of
atherosclerotic vascular injury. Another current hypothesis is
that direct colonization of the vessel wall initiates local cell
autoimmune reactions by activation of antigen-presenting cells
(17).
Evidence for Protective Effect of Influenza
Vaccination Against Cardiovascular Events
The AHA/ACC recommends annual influenza vaccination as
secondary prevention for individuals with coronary and other
atherosclerotic vascular disease (Class I, Level B) (4). (Def-
initions of the ACC/AHA classes of recommendations and
levels of evidence are listed in the Appendix.) This recom-
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mendation, issued in 2006, reflects the growing body of
evidence that influenza vaccination is protective against
cardiovascular events for individuals with known CVD (18–
24). In addition, no evidence suggests that influenza vacci-
nation is harmful for individuals with cardiovascular condi-
tions (25).
The strongest evidence for a protective effect comes from
a randomized, controlled trial of influenza vaccination (FLU
Vaccination in Acute Coronary Syndromes [FLUVACS]) in
which 301 patients hospitalized for either myocardial infarc-
tion (MI) or planned angioplasty/stenting were randomly
assigned to receive influenza vaccination or remain unvacci-
nated (18,19). At 1 year, the relative risk of cardiovascular
mortality in the vaccinated group was 0.25 (95% confidence
interval [CI] 0.07 to 0.86) compared with the unvaccinated
group (overall rates 2% versus 8%), and the relative risk of a
composite end point (cardiovascular death, nonfatal MI, or
severe ischemia) was 0.59 (95% CI 0.30 to 0.86; 11% versus
23%) (18). At 2 years, although risk reductions of similar
magnitude were measured, the remaining sample size after
loss to follow-up was too small to find statistical significance
(19). Of note, the FLUVACS trial was conducted without
financial support from the influenza vaccine industry.
Other evidence supporting a protective effect of influenza
vaccination stems from cohorts of elders identified through
health plans as well as from clinically derived case-control
analyses (22–24). Two studies indicate vaccine-associated sig-
nificant reductions in the risk of hospitalization, specifically for
individuals with congestive heart failure (20,21). A third study
reports a significant reduction in the risk of cerebrovascular
accidents (CVAs) associated with influenza vaccination (23).
The principal limitation of these or any cohort and case-control
analyses is that lower event risks may be confounded by
sociodemographic and health factors also associated with influ-
enza vaccination (20 –24).
No study has indicated higher rates of cardiovascular
events for individuals who receive influenza vaccination. A
recent multiyear cohort study of 39 000 patients with CVD
(either MI or CVA) in the United Kingdom found no
increased risk of MI or CVA in the 90-day period immedi-
ately after influenza vaccination (25). In fact, incidence rates
of MI and CVA were significantly lower in the 28 days after
vaccination than in the period immediately preceding vacci-
nation, though these differences disappeared with adjustment
for age. Another multiyear study of a cohort of private health
plan enrollees who were identified on the basis of a hospi-
talization for nonfatal first MI reported no protective effect
associated with influenza vaccination (26). The primary
contrast between this negative study and others that support a
protective effect for influenza vaccination is that this study
population was generally younger (26).
Overall, the majority of published evidence indicates that
influenza vaccination is associated with a significantly re-
duced risk of cardiovascular events for individuals with
known coronary and other atherosclerotic conditions, includ-
ing prior CVA. The sole randomized trial of influenza
vaccination among persons with CVD (FLUVACS) demon-
strated significant reductions in cardiovascular mortality and
in a composite end point including death, nonfatal MI, and
ischemia at 1 year (18,19). Future trials should elucidate
further the relative benefits of influenza vaccination for
younger versus older persons with CVD. Currently, data from
FLUVACS (which included patients younger than 65 years
but did not distinguish them from older patients in analyses)
(27) and other studies support the recommendation of influ-
enza vaccination for persons of all ages with CVD.
Low Vaccination Coverage Rates Among Persons
With CVD
The AHA and ACC recommend that the12 million persons in
the United States with cardiovascular conditions get annual
influenza vaccination (2,28). Current influenza vaccination cov-
erage among persons with heart disease is far below national
coverage goals set in Healthy People 2010 (60% for persons
65 years of age; 90% for persons 65 years of age): Only
1 in every 3 adults with heart disease (34%) received influenza
vaccination in 2005 (Behavioral Risk Factor Surveillance Sys-
tem; CDC, unpublished data), a level of coverage that is
essentially unchanged from other below-target rates achieved in
2002 (29). In 2005, vaccination coverage among older adults
(65 years old) with heart disease was much higher (71%) than
among middle-aged (50 to 64 years old) and younger (18 to 49
years old) adults with heart disease (41% and 23%, respec-
tively). Non-Hispanic white adults had similar influenza vacci-
nation rates (38%) to black adults (36%), but rates in both groups
were higher than among Hispanic adults (30%).
Failure to vaccinate persons with cardiovascular conditions
and disparities in vaccination coverage across age categories and
ethnic groups represent major opportunities for healthcare pro-
viders to improve the care of this patient population. A central
barrier to vaccination against influenza is that only about one
half of cardiology practices nationwide stock influenza vaccine,
as opposed to 70% of endocrinology practices and of generalist
primary care practices and 90% of pulmonology practices (5,30).
Outpatient visits to cardiology practices present a superb but
frequently missed opportunity to administer influenza vaccine to
millions of adults with CVD (31), as do outpatient visits in
primary care settings and hospitalizations for cardiovascular
causes. A recent study suggests that the most effective ways to
improve influenza vaccination rates among nonelderly adults
with heart disease are for cardiology practices to have influenza
vaccine available in their offices for patient visits, for cardiovas-
cular care providers to strongly recommend vaccination to their
patients during vaccination season, and for practices to imple-
ment standing-orders protocols that permit staff to administer
influenza vaccine to patients with cardiovascular indications
without waiting in each case for a physician’s order (6).
It is important to emphasize that strong recommendations
from health professionals about vaccination against influenza
can be very influential, especially for urban, predominantly
black patients (32). Patient-level barriers to influenza vacci-
nation, specifically for persons with CVD, have not been well
characterized and should be examined in future research.
Providers and practices that provide care for patients with
CVD should stock influenza vaccine annually. There is a choice
of manufacturers, and the vaccines are considered equally
effective. Ordering information for all manufacturers licensed to
provide influenza vaccine in the United States for the 2006/2007
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season is provided on the American Heart Association Web
site (www.americanheart.org) and in the Table.
Conclusions
Seasonal influenza represents a major preventable threat to
the health of persons with CVD. Clinical trials and observa-
tional studies have demonstrated that vaccination against
influenza is associated with significantly reduced risk of
cardiovascular death and nonfatal events. Vaccination is
currently recommended for persons with diabetes, a condition
common to patients with CVD (33). On the basis of this
evidence, the AHA and ACC recommend inactivated influ-
enza vaccination as a component of secondary prevention for
persons with coronary disease and other atherosclerotic vascular
conditions (Class I, Level B). This level of recommendation is
based on the judgment that influenza vaccination should be
administered to all persons with CVD (unless they have a
contraindication to receiving the vaccine) and on evidence from
a single randomized clinical trial and several nonrandomized
population cohort studies.
Currently, below-target vaccination rates and disparities in
vaccination coverage across different ethnic groups represent
missed opportunities to maximize the preventive benefits of
influenza vaccination. Providers who care for patients with
CVD can increase influenza vaccination coverage among
their patients by stocking the vaccine and promoting annual
vaccination immunization with strong recommendations and stand-
ing orders.
Appendix
ACC/AHA Classes of Recommendation and Levels of Evidence
Class of Recommendation
Class I Conditions for which there is evidence and/or general agreement that a given procedure/therapy is beneficial, useful, and
effective.
Class II Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of performing
the procedure/therapy.
Class IIa Weight of evidence/opinion is in favor of usefulness/efficacy.
Class IIb Usefulness/efficacy is less well established by evidence/opinion.
Class III Conditions for which there is evidence and/or general agreement that a procedure/therapy is not useful or effective and in
some cases may be harmful.
Level of Evidence
Level of Evidence A Data derived from multiple randomized clinical trials or meta-analyses.
Level of Evidence B Data derived from a single randomized trial or nonrandomized studies.
Level of Evidence C Only consensus opinion of experts, case studies, or standard-of-care.
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TABLE. How Providers Can Place an Order for Influenza Vaccine in the United States
Influenza Vaccine Manufacturers*
(Alphabetical Order) How to Order for the 2006/2007 Influenza Season†‡
GlaxoSmithKline Call Flurix Service Center at 1-866-475-8222 (choose option 1).
Novartis (formerly Chiron) Call 1-800-244-7668 (choose option 2) to receive a list of vaccine distributors in your area.
Sanofi Pasteur Set up a provider account and then place order at http://www.vaccineshoppe.com.
*These are manufacturers of inactivated trivalent influenza vaccine. Live, attenuated intranasal influenza vaccine (FluMist;
MedImmune) is not recommended for individuals with cardiovascular conditions.
†Providers are encouraged to order vaccine in the spring and summer for delivery in the fall before each influenza season.
‡Providers who wish to have more information about influenza vaccine should contact their local or state public health departments.
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